




Housekeeping

Housekeeping

- Click **Mute/Unmute**  to turn your microphone on/off. Please keep your microphone on Mute if you are not speaking.
- Click **Start/Stop Video**  to turn your webcam on/off.
- To ask a question, send the Chair a direct message using the **Chat** function. 
The Chair will invite you to ask your question to the group.
- There will be a series of polls throughout the AGM to record your votes. Voting is anonymous.
- The meeting is being recorded, as is the requirement of our society regulations.
- We record a list of the meeting attendees and outcomes of the voting, as is the requirement of our society regulations. We will need to send detailed information of our AGM to the Amtsgericht Mannheim (Registergericht).



ESGCT Annual General Meeting



16 December 2021
Virtual AGM - Zoom

Agenda

- I. Opening and welcome
- II. Confirmation of the agenda
- III. Approval of minutes of the AGM of 16 September 2020
- IV. Year 2021: Overview
- V. ESGCT board: Confirmation and mandate for prolonging term
- VI. Report of Treasurer: 2020 accounts
- VII. Discharge of Executive Board and formal approval of 2020 accounts
- VIII. Report of the President
- IX. AOB



Agenda

I. Opening and welcome

II. Confirmation of the agenda

III. Approval of minutes of the AGM of 16 September 2020

IV. Year 2021: Overview

V. ESGCT board: Confirmation and mandate for prolonging term

VI. Report of Treasurer: 2020 accounts

VII. Discharge of Executive Board and formal approval of 2020 accounts

VIII. Report of the President

IX. AOB



Agenda

I. Opening and welcome

II. Confirmation of the agenda

III. Approval of minutes of the AGM of 16 September 2020

IV. Year 2021: Overview

V. ESGCT board: Confirmation and mandate for prolonging term

VI. Report of Treasurer: 2020 accounts

VII. Discharge of Executive Board and formal approval of 2020 accounts

VIII. Report of the President

IX. AOB



Agenda

I. Opening and welcome

II. Confirmation of the agenda

III. Approval of minutes of the AGM of 16 September 2020

IV. Year 2021: Overview

V. ESGCT board: Confirmation and mandate for prolonging term

VI. Report of Treasurer: 2020 accounts

VII. Discharge of Executive Board and formal approval of 2020 accounts

VIII. Report of the President

IX. AOB



Agenda

- I. Opening and welcome
- II. Confirmation of the agenda
- III. Approval of minutes of the AGM of 16 September 2020

IV. Year 2021: Overview

- V. ESGCT board: Confirmation and mandate for prolonging term
- VI. Report of Treasurer: 2020 accounts
- VII. Discharge of Executive Board and formal approval of 2020 accounts
- VIII. Report of the President
- IX. AOB



European Society of Gene and Cell Therapy



Back in time

Thomas
et al.
1959
First **BMT**
(identical
twins)

Rogers and
Pfuderer
1968
First **virus-
mediated
gene
transfer**

Horowitz
et al.
1975
SCID is first
disease treated
with matched
unrelated
donor **HSCT**

Rosenberg
et al.
1989
First application
of **gene-marked
cells in humans**

Molineux
et al.
1990
**G-CSF
mobilized
blood** as
source
for HSCT

Giralt
et al.
1997
Non-myelo-
ablative
**conditioning
regimen**

Gaudet
et al.
2012
First approval
of a gene
therapeutic
(**Glybera®**)
in the EU

- Safety improved vector design
- Development of advanced assays for risk assessment

**2007 - European Society
of Gene & Cell Therapy**

1950 1960 1970 1980 1990

Gammaretroviral

ADA-SCID 1990

First gene therapy clinical trial
(gene-modified T cells)

ADA-SCID, SCID-X1, CGD, WAS 1992–2006

Initiation of clinical trials with gene-modified HSC

**CLINICAL TRIALS
HSC**

**EUROPEAN WORKING GROUP ON
HUMAN GENE TRANSFER AND THERAPY**

First Elected BOARD

C. Bordignon (President)
O. Cohen-Haguenauer
(Scientific Secretary)
O. Danos & J.M. Heard
S. Russell
D. Valerio
T. Velu (Treasurer)
E. Wagner

E.W.G.T.
European Working Group
on Human Gene Transfer
and Therapy
SCIENTIFIC SECRETARIAT / CENTRAL OFFICE
HÔPITAL SAINT-LOUIS 75471 PARIS Cedex 10 FRANCE
EWGT - MEETINGS

**1991 - Foundations of ESGCT:
an international workshop**

**1992 - European Working Group on Human
Gene Transfer and Therapy**




Market approval in Western World

➤ 2012: first gene therapy approved in Western World by EMA*

ex vivo

- Strimvalis
- Kymriah
- Zynteglo
- Yescarta
- Libmeldy
- Tecartus
- Skysona



in vivo

- Glybera
- Luxturna
- Zolgensma
- Imlygic

* European Medicines Agency; Image: Kaufmann et al. EMBO Mol. Med. 2013





European Society of Gene and Cell Therapy

29 years



ESGCT seeks to support **students, scientists and clinicians** working in the fields of gene and cell therapy.


ESGCT advances research and clinical application of **gene therapy, cell therapy and genetic vaccination** by building awareness and understanding, through **scientific and educational activities**, and promotion and **exchange of information and ideas**.



ESGCT 2011 to 2021



Number of ESGCT Members 2011-2021



Hildegard Büning
President



Juan Bueren
Vice-President



Alberto Auricchio
Secretary



Axel Schambach
Treasurer



Alessandro Aiuti



Your ESGCT Board



Claire Booth



Vincenzo Cerullo



Giuliana Ferrari



***Gloria Gonzalez-
Aseguinolaza***



Zoltan Ivics

Eirini Vamva



Vanessa Woods



Your student Board Members



European Society of Gene and Cell Therapy

2021



e-SCHOOL
STAY CONNECTED



e-SEMINARS
KEEP UP-TO-DATE

Series 2: Gene Editing

February 2021

with the kind support of 



Virgis Siksnyis, Vilnius University,
Institute of Biotechnology
**Repurposing of bacterial CRISPR-Cas immunity
for genome editing**




Laura Sepp-Lorenzino, Executive Vice President,
Chief Scientific Officer, Intellia Therapeutics
**Intellia's Modular CRISPR/Cas9 Gene Editing
Platform for the Treatment of Disease**



Toni Cathomen, University of Freiburg
**Safety considerations in therapeutic
genome editing**

- 3 presentations
- 156 live viewers
- 603 post-live views

<i>VIRTUAL CONGRESS</i>		
2021		19.10
		- 22.10



**EUROPEAN
SOCIETY OF
GENE & CELL
THERAPY**

1378 registrations from 40 countries

434 Academic (334 members / 100 non-members)


706 Industry (410 members / 296 non-members)

237 Students (212 members / 25 non-members).

154 student members submitted an abstract (free registration)

289 sponsors and exhibitors (from 47 companies/institutions)

945 (69%) of the attendees never attended an ESGCT meeting before





PARALLEL 1c

CAR T & CAR NK cells



Chairs: **Hinrich Abken**,
Universitätsklinikum Regensburg
Dirk Nettelbeck,
DKFZ, Heidelberg

Other societies @ ESGCT virtual



PARALLEL 2a

Primary immunodeficiencies



Chairs: **Rajvinder Karda**,
University College London
Robyn Bell,
Imperial College London



PARALLEL 2b

Gene editing I



Chairs: **Adi Barzel**,
Tel Aviv University
Ayal Hendel,
Bar-Ilan University, Tel Aviv



PARALLEL 2c

Immunotherapy for cancer
& CAR T cells



Chairs: **José Antonio Pérez-Simón**,
Institute of Biomedicine of Sevilla
Felipe Prósper,
University of Navarra



PARALLEL 3b

Cardiovascular & lung
diseases



Chairs: **Annakaisa Tirronen**,
University of Eastern Finland, Kuopio
Seppo Ylä-Herttuala,
University of Eastern Finland, Kuopio



PARALLEL 4b

Gene editing II



Chairs: **Rob Collin**,
*Radboud University Medical
Center, Nijmegen*
Massimiliano Caiazzo,
Utrecht University



PARALLEL 5b

Gene editing III



Chairs: **Mario Amendola**,
Genethon, Evry
Annarita Miccio,
Institut Imagine, Paris



PARALLEL 8c

Cutting edge gene and cell
therapy research in America



Chairs: **Stephen Russell**,
Mayo Clinic, Rochester, MA
Beverly Davidson, ASGCT President,
Children's Hospital of Philadelphia

ESGCT Virtual 2021

34 sessions
79 invited speakers
75 selected orals
374 e-Posters
47 sponsors and exhibitors
27 virtual booths

VOD & POST EVENT STATS

16,725 TOTAL e-posters views
5393 TOTAL video on Demand views



LIVE EVENT

1260 delegates attended the live event
10,021 e-posters views
1007 exhibitor booth visits
1740 video on Demand views

ESGCT Virtual 2021

34 sessions
79 invited speakers
75 selected orals
374 e-Posters
47 sponsors and exhibitors
27 virtual booths

VOD & POST EVENT

16,725 TOTAL e-posters views
5393 TOTAL video on Demand views



Thierry
VandenDriessche



EVENT

gates attended the live event
posters views
exhibitor booth visits
1740 video on Demand views

Diamond



Platinum



Gold



ADVERUM
BIOTECHNOLOGIES

AFMTELETHON
CURE THROUGH INNOVATION

ArcticZymes®

CellGenix

CERGENTIS
Genetic Engineering

COMECER
an  company

GenoSafe

KCT
Kuopio Center
for Gene and Cell Therapy

Lonza
Cell & Gene

MEIRAGTx

myriade

OriGen
BIOMEDICAL

PassageBio

Vivet
THERAPEUTICS

Polyplus⁺
transfection®

PROGEN
Making gene therapy better. Together.

VGXI®
QUALITY....IT'S IN OUR DNA®

PerkinElmer®
For the Better

SwanBio
THERAPEUTICS

astellas
GENE THERAPIES

FORGE
BIOLOGICS

FREELINE

TAYSHA
GENE THERAPIES

xcell

greiner
BIO-ONE

MERCK

PlasmidFactory®
The Minicircle Company

SARTORIUS

Silver

Bronze

Agenda

- I. Opening and welcome
- II. Confirmation of the agenda
- III. Approval of minutes of the AGM of 16 September 2020
- IV. Year 2021: Overview

V. ESGCT board: Confirmation and mandate for prolonging term

- VI. Report of Treasurer: 2020 accounts
- VII. Discharge of Executive Board and formal approval of 2020 accounts
- VIII. Report of the President
- IX. AOB



Board prolongation

Due to the cancellation of in person congresses, the election of the board will be postponed to the next congress in Edinburgh 2022. We need to vote for the existing board to remain in their post until the upcoming congress.

Executive Board

- Hildegard Büning: President
- Juan Bueren: President Elect
- Axel Schambach: Treasurer
- Alberto Auricchio: General Secretary

Confirmation of the posts of the above mentioned board members

Board

- Alessandro Aiuti
- Claire Booth
- Gloria Gonzalez Aseguinolaza
- Vincenzo Cerullo
- Zoltan Ivics
- Giuliana Ferrari

Confirmation of the posts of the above mentioned board members



Agenda

- I. Opening and welcome
- II. Confirmation of the agenda
- III. Approval of minutes of the AGM of 16 September 2020
- IV. Year 2021: Overview
- V. ESGCT board: Confirmation and mandate for prolonging term
- VI. Report of Treasurer: 2020 accounts**
- VII. Discharge of Executive Board and formal approval of 2020 accounts
- VIII. Report of the President
- IX. AOB





Profit and Loss – cash basis

For the year ended 31 December 2020

Turnover	
Grants	-
Journal Contribution	1.490,00
Membership	25.579,32
Registration Fee	- 400,00
Sales	142.995,00
Total Turnover	169.664,32
Cost of Sales	
Event costs	90.698,48
Card Processing Fees	636,76
Fundraising & Sponsor Management	110.595,37
Gifting	2.000,00
IT, internet & data	20.179,46
Marketing & advertising	1.186,58
Planning meeting	5.885,77
Profit Share	80.000,00
Venue catering	896,50
Total Cost of Sales	312,078.92
Gross Profit	- 142.414,60

Administrative Costs	
Association Management	27.648,85
Accountancy Fees	5.037,49
Awards	503,73
Bank fees	1.140,76
Consultancy - Design	1.110,63
Credit Card Fees	52,06
General Expenses	214,14
Legal Expenses	555,43
Postage, Freight & Courier	-
Travel - International	638,95
Total Administrative Costs	36.902,44
Operating Profit	- 179.317,04

Accounts 2019 - all in € EURO	31/12/2020
Cash in bank	
Cashflow account	
Safety account	
Congress Account	47.188,14
Main Account	897.995,11
Stripe	587,22



Agenda

- I. Opening and welcome
- II. Confirmation of the agenda
- III. Approval of minutes of the AGM of 16 September 2020
- IV. Year 2021: Overview
- V. ESGCT board: Confirmation and mandate for prolonging term
- VI. Report of Treasurer: 2020 accounts

VII. Discharge of Executive Board and formal approval of 2020 accounts

- VIII. Report of the President
- IX. AOB



Agenda

- I. Opening and welcome
- II. Confirmation of the agenda
- III. Approval of minutes of the AGM of 16 September 2020
- IV. Year 2021: Overview
- V. ESGCT board: Confirmation and mandate for prolonging term
- VI. Report of Treasurer: 2020 accounts
- VII. Discharge of Executive Board and formal approval of 2020 accounts
- VIII. Report of the President**
- IX. AOB



ESGCT seeks to support **students, scientists and clinicians** working in the fields of gene and cell therapy.

ESGCT advances research and clinical application of **gene therapy, cell therapy and genetic vaccination** by building awareness and understanding, through **scientific and educational activities**, and promotion and **exchange of information and ideas**.





eSchool & eSeminars

ESGCT e-School 2020 Series

ESGCT e-School 2020
Series Summary



29 Presentations

Streamed from 06 May 2020 to 16 December 2020, with one month break in August



2,393 total live views
83 average number of live viewers per video




10,061 total post-live views
437 average number of post-live views per video





843 YouTube Subscribers

685 subscribed between 06 May 2020 and 04 January 2021

Viewer Type



Viewer Age



* Post-live views and subscriber count as of 04/01/21

ESGCT eSeminar 20-21 series



6

Seminars



2574

total live views



6.5


hours of presentations




3318

post views

Viewer type



Country





Our Journal

Our Journal


Impact Factor: 5.695

2021 Special issues:

- CRISPR/Cas
- Oncolytic viruses
- Pulmonary diseases
- Women in Gene Therapy
- CNS Gene Therapy



2021 ESGCT Special Issue of HGT



- Unique as national Gene therapy societies and ESGCT joint forces
- Cover by Dr. Vivian Budnik (UMASS)
- X review articles by the national societies of Europe
- X unique publications

The Official Journal of

EUROPEAN SOCIETY OF
GENE & CELL THERAPY





Partnerships

National Gene Therapy Societies in Europe



Sociedad Española

Terapia Génica y Celular



Suomen geeni- ja soluterapiaseura
Finnish Society of Gene and Cell Therapy



Société Française
de Thérapie Cellulaire
et Génique
SFTCG

British
Society
for
Gene &
Cell
Therapy



HELLENIC SOCIETY
OF GENE THERAPY AND
REGENERATIVE MEDICINE



DG-GT

Deutsche
Gesellschaft für
Genterapie e.V.

NVGCT




Nederlandse Vereniging
voor Gen- & Celtherapie



ISGCT
The Israeli Society
of Gene & Cell Therapy

...and around the world





Our awards

ESGCT Achievement Awards



Outstanding Achievement Award 2021

Awarded to one individual each year who has made extraordinary
contributions to the field



Outstanding Achievement Award

Fulvio Mavilio



Young Investigator Awards

Up to 3 winners each year, awarded to up-and-coming young researchers already making a significant impact on the field




Young Investigator Award

Maria Ester Bernado



Julian Grünewald





Future ESGCT events

- 27 -29 April 2022 - Spring school, Athens
- 11 to 14 October 2022 – EICC, Edinburgh
- 24 to 27 October 2023 – Square, Brussels



Edinburgh 2022

ESGCT 29th
Congress
in collaboration
with BSGCT

Edinburgh
International
Conference
Center

10 - 14 October



**EUROPEAN
SOCIETY OF
GENE & CELL
THERAPY**


British
Society
for
Gene &
Cell
Therapy

ESGCT SPRING SCHOOL 2022

Athens, Greece, 27-29 April

An intensive 3-day course for MD and Phd Students, free of charge for 150 students operated on a first come, first served basis, giving priority to those who have never attended a Spring School before.

- Outstanding talks by leading experts in the field
- Many opportunities to network with European leaders in gene therapy
- Pre-event workshops



We look forward to seeing you soon!

